Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Testicular cancer in 2013

Towards personalized medicine—are we there yet?

The pursuit of reduced-intensity treatments for testicular cancer continued with vigour in 2013. For those with metastatic disease and poor prognoses, an alternative to bleomycin, etoposide and cisplatin chemotherapy emerged. These advances suggest we are making progress by reducing treatment intensity with personalized approaches for this highly curable malignancy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol. 15, 594–603 (1997).

  2. Feldman, D. R., Bosl, G. J., Sheinfeld, J. & Motzer, R. J. Medical treatment of advanced testicular cancer. JAMA 299, 672–684 (2008).

    Article  CAS  Google Scholar 

  3. Fizazi, K., Pagliaro, L. C., Flechon, A. & Mardiak, J. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13 [abstract LBA4500]. J. Clin. Oncol. 31 (Suppl.), LBA4500 (2013).

    Article  Google Scholar 

  4. Olofsson, S. E. et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J. Clin. Oncol. 29, 2032–2039 (2011).

    Article  Google Scholar 

  5. Fizazi, K. et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J. Clin. Oncol. 22, 3868–3876 (2004).

    Article  Google Scholar 

  6. Oldenburg, J. et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 (Suppl. 6), vi125–vi132 (2013).

    PubMed  Google Scholar 

  7. Horwich, A., Dearnaley, D. P., Sohaib, A., Pennert, K. & Huddart, R. A. Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann. Oncol. 24, 2104–2107 (2013).

    Article  CAS  Google Scholar 

  8. Tandstad, T. et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J. Clin. Oncol. 27, 2122–2128 (2009).

    Article  Google Scholar 

  9. Tandstad, T. et al. One course of adjuvant BEP in clinical stage I, nonseminoma: mature and expanded results from the SWENOTECA group [abstract 4553]. J. Clin. Oncol. 31 (Suppl.), a4553 (2013).

    Google Scholar 

  10. Fung, C., Fosså, S. D., Milano, M. T., Oldenburg, J. & Travis, L. B. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J. Clin. Oncol. 31, 3807–3814 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sophie D. Fosså.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oldenburg, J., Fosså, S. Towards personalized medicine—are we there yet?. Nat Rev Urol 11, 68–69 (2014). https://doi.org/10.1038/nrurol.2013.298

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2013.298

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer